Similar articles

• Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer.

  Xue L, Yu X, Zhao L, Garrett A, Wu D, Liu HY. Xue L, et al. Mol Pharm. 2024 Nov 4;21(11):5749-5760. doi: 10.1021/acs.molpharmaceut.4c00743. Epub 2024 Oct 10. Mol Pharm. 2024. PMID: 39388218
• Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.

  Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Sandhu S, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ayati N, Niu C, Hofman MS, Martin AJ, Thomas H, Davis ID, Stockler MR; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Lancet Oncol. 2025 Jul 30:S1470-2045(25)00339-0. doi: 10.1016/S1470-2045(25)00339-0. Online ahead of print. Lancet Oncol. 2025. PMID: 40752515
• Reciprocal regulation between RACGAP1 and AR contributes to endocrine therapy resistance in prostate cancer.

  Wang J, Liu H, Yu Z, Zhou Q, Sun F, Han J, Gao L, Dou B, Zhang H, Fu J, Jia W, Chen W, Hu J, Han B. Wang J, et al. Cell Commun Signal. 2024 Jun 19;22(1):339. doi: 10.1186/s12964-024-01703-w. Cell Commun Signal. 2024. PMID: 38898473 Free PMC article.
• Third-line treatment and ¹⁷⁷Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.

  von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. von Eyben FE, et al. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508. doi: 10.1007/s00259-017-3895-x. Epub 2017 Dec 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29247284 Free PMC article.
• Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.

  Chen X, Wang Q, Pan Y, Wang S, Li Y, Zhang H, Xu M, Zhou H, Liu X. Chen X, et al. Front Endocrinol (Lausanne). 2023 Mar 9;14:1134719. doi: 10.3389/fendo.2023.1134719. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36967752 Free PMC article.